Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PCVX
stocks logo

PCVX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.530
+50%
--
--
-1.577
+51.68%
--
--
-1.605
+31.56%
Estimates Revision
The market is revising No Change the revenue expectations for Vaxcyte, Inc. (PCVX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.52%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+7.04%
In Past 3 Month
Stock Price
Go Up
up Image
+39.52%
In Past 3 Month
Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 75.80 USD with a low forecast of 38.00 USD and a high forecast of 116.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 75.80 USD with a low forecast of 38.00 USD and a high forecast of 116.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 46.070
sliders
Low
38.00
Averages
75.80
High
116.00
Current: 46.070
sliders
Low
38.00
Averages
75.80
High
116.00
BTIG
Thomas Shrader
Buy
downgrade
$160 -> $85
2025-10-16
Reason
BTIG
Thomas Shrader
Price Target
$160 -> $85
2025-10-16
downgrade
Buy
Reason
BTIG analyst Thomas Shrader lowered the firm's price target on Vaxcyte to $85 from $160 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.
Goldman Sachs
Neutral
initiated
$38
2025-09-12
Reason
Goldman Sachs
Price Target
$38
2025-09-12
initiated
Neutral
Reason
Goldman Sachs initiated coverage of Vaxcyte with a Neutral rating and $38 price target. The firm believes the company's vaccine-focused platform provided "validating" data for its flagship pneumococcal conjugate vaccine franchise over the past three years, positioning Vaxcyte to be a leading player in the "large and established" pneumococcal vaccine market. However, an extended timeline to the company's next catalyst, the Phase 3 data in adults in late 2026, along with regulatory uncertainty related to vaccines will cap the stock's performance in the near term, the analyst tells investors in a research note.
TD Cowen
Tara Bancroft
Buy
downgrade
$85 -> $50
2025-08-07
Reason
TD Cowen
Tara Bancroft
Price Target
$85 -> $50
2025-08-07
downgrade
Buy
Reason
TD Cowen analyst Tara Bancroft lowered the firm's price target on Vaxcyte to $50 from $85 and keeps a Buy rating on the shares. The firm is confident that VAX-31 in adults should lead to robust immunogenicity and protection, resulting in a large market. In infants, though TD Cowen is heartened that the Phase II is moving forward with an optimized dose, this extends the data timeline to the first half of 2027. The firm remains confident in the success of the adult and infant programs.
Mizuho
Salim Syed
Outperform
maintain
2025-06-21
Reason
Mizuho
Salim Syed
Price Target
2025-06-21
maintain
Outperform
Reason
Cantor Fitzgerald
Carter Gould
Buy
Initiates
n/a
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
n/a
2025-04-22
Initiates
Buy
Reason
Cantor Fitzgerald analyst Carter Gould initiated coverage of Vaxcyte with an Overweight rating.
Needham
Joseph Stringer
Strong Buy
Reiterates
$90
2025-04-08
Reason
Needham
Joseph Stringer
Price Target
$90
2025-04-08
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vaxcyte Inc (PCVX.O) is -7.50, compared to its 5-year average forward P/E of -12.06. For a more detailed relative valuation and DCF analysis to assess Vaxcyte Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.06
Current PE
-7.50
Overvalued PE
-7.83
Undervalued PE
-16.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-5.26
Undervalued EV/EBITDA
-15.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
573.91
Current PS
0.00
Overvalued PS
1681.57
Undervalued PS
-533.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PCVX News & Events

Events Timeline

(ET)
2025-11-04
16:19:40
Vaxcyte Announces Q3 Earnings Per Share of $1.56, Exceeding Consensus Estimate of $1.25
select
2025-09-30 (ET)
2025-09-30
08:36:32
Vaxcyte to set up fill-finish production facility in North Carolina
select
2025-09-03 (ET)
2025-09-03
07:35:13
Vaxcyte progresses with Phase 2 study of VAX-31 for infants
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
00:10 AMBarron's
The Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
  • Biotech Sector Performance: The State Street SPDR S&P Biotech ETF has shown a poor performance since early 2021, indicating challenges for investors in the biotech sector.
  • Investor Sentiment: The overall trend in the biotech market suggests a significant downturn, leading to a negative outlook for potential investors.
[object Object]
Preview
9.0
12-02MarketWatch
Vaccine Shares Drop After FDA Official Connects COVID Vaccines to Heart Issues in Young Men

  • Market Reaction: Shares of Moderna and BioNTech fell on Monday morning following a memo from a FDA official linking COVID-19 mRNA vaccines to myocarditis deaths in 10 children.

  • Public Concern: The potential link between mRNA vaccines and myocarditis, especially in teenage boys and young men, has fueled arguments against vaccinating children with these vaccines.

[object Object]
Preview
4.5
12-01Benzinga
CleanSpark, Cipher Mining, Bitdeer Technologies, and Other Major Stocks Decline in Monday's Pre-Market Trading

  • U.S. Stock Market Trends: U.S. stock futures are down, with the Dow futures dropping approximately 200 points, reflecting a bearish sentiment in the market.

  • Crypto-Linked Stocks Performance: Shares of crypto-related companies, including CleanSpark Inc, fell significantly in pre-market trading as Bitcoin's value dropped below $86,000.

  • Notable Stock Declines: Several stocks experienced sharp declines in pre-market trading, including Columbus Circle Capital I Corp (-19.2%) and Vaxcyte Inc (-11.6%).

  • General Market Sentiment: The overall market sentiment appears negative, with multiple stocks in the tech and crypto sectors showing substantial losses following the decline in Bitcoin prices.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vaxcyte Inc (PCVX) stock price today?

The current price of PCVX is 46.07 USD — it has decreased -3.42 % in the last trading day.

arrow icon

What is Vaxcyte Inc (PCVX)'s business?

Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

arrow icon

What is the price predicton of PCVX Stock?

Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 75.80 USD with a low forecast of 38.00 USD and a high forecast of 116.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vaxcyte Inc (PCVX)'s revenue for the last quarter?

Vaxcyte Inc revenue for the last quarter amounts to -242.38M USD, increased 73.58 % YoY.

arrow icon

What is Vaxcyte Inc (PCVX)'s earnings per share (EPS) for the last quarter?

Vaxcyte Inc. EPS for the last quarter amounts to -155351000.00 USD, increased 57.26 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vaxcyte Inc (PCVX)'s fundamentals?

The market is revising No Change the revenue expectations for Vaxcyte, Inc. (PCVX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.52%.
arrow icon

How many employees does Vaxcyte Inc (PCVX). have?

Vaxcyte Inc (PCVX) has 414 emplpoyees as of December 05 2025.

arrow icon

What is Vaxcyte Inc (PCVX) market cap?

Today PCVX has the market capitalization of 6.03B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free